US Stem Cell (USRM) Stock Statistics & Valuation Metrics
Total Valuation
US Stem Cell has a market cap or net worth of $64.15K. The enterprise value is $9.01T.
- Market Cap
- $64.15K
- Enterprise Value
- $9.01T
Share Statistics
US Stem Cell has 641,507,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 641,507,300
- Owned by Insiders
- ―
- Owned by Institutions
- 0.02%
Financial Efficiency
US Stem Cell’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 29.95%.
- Return on Equity (ROE)
- 0.19
- Return on Assets (ROA)
- -42.00
- Return on Invested Capital (ROIC)
- 29.95%
- Return on Capital Employed (ROCE)
- 0.12
- Revenue Per Employee
- 7,459
- Profits Per Employee
- -259.81K
- Employee Count
- 11
- Asset Turnover
- 1.21
- Inventory Turnover
- 24.25
Valuation Ratios
The current PE Ratio of US Stem Cell is -0.02. US Stem Cell’s PEG ratio is -0.00.
- PE Ratio
- -0.02
- PS Ratio
- 0.78
- PB Ratio
- -0.00
- Price to FCF
- -0.21
- Price to Operating Cash Flow
- -0.19
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, US Stem Cell had revenue of 82.05K and earned -2.86M in profits. Earnings per share was -0.00.
- Revenue
- 82.05K
- Gross Profit
- 58.28K
- Operating Income
- -1.72M
- Pretax Income
- -2.86M
- Net Income
- -2.86M
- EBITDA
- -2.17M
- Earnings Per Share (EPS)
- -0.00
Cash Flow
In the last 12 months, operating cash flow was -304.85K and capital expenditures 0, giving a free cash flow of -304.85K billion.
- Operating Cash Flow
- -304.85K
- Free Cash Flow
- -304.85K
- Free Cash Flow per Share
- -0.00
Dividends & Yields
US Stem Cell pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -475.21%
- Earnings Yield
- -4831.21%
Stock Price Statistics
- Beta
- -125.88
- 52-Week Price Change
- -99.80%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Financial Position
US Stem Cell as a current ratio of 0.00, with Debt / Equity ratio of -60.68%
- Current Ratio
- 0.00
- Quick Ratio
- 0.00
- Debt to Market Cap
- 3.15
- Net Debt to EBITDA
- -4.12
- Interest Coverage Ratio
- -2.49
Taxes
In the past 12 months, US Stem Cell has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
US Stem Cell EV to EBITDA ratio is -4.15, with an EV/FCF ratio of -29.54.
- EV to Sales
- 109.76
- EV to EBITDA
- -4.15
- EV to Free Cash Flow
- -29.54
- EV to Operating Cash Flow
- -29.54
Balance Sheet
US Stem Cell has $5,133.00 in cash and marketable securities with $8.95M in debt, giving a net cash position of -$8.94M billion.
- Cash & Marketable Securities
- $5,133.00
- Total Debt
- $8.95M
- Net Cash
- -$8.94M
- Net Cash Per Share
- -$0.01
- Tangible Book Value Per Share
- -$0.02
Margins
Gross margin is 71.03%, with operating margin of -2096.90%, and net profit margin of -3483.21%.
- Gross Margin
- 71.03%
- Operating Margin
- -2096.90%
- Pretax Margin
- -3483.21%
- Net Profit Margin
- -3483.21%
- EBITDA Margin
- -2642.28%
- EBIT Margin
- -2642.28%
Analyst Forecast
The average price target for US Stem Cell is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―